What stage does Finchley Healthcare Ventures invest at?

Finchley Healthcare Ventures invests at the Seed, Series A, Series B, Late Stage stages.

What sectors does Finchley Healthcare Ventures focus on?

Finchley Healthcare Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Finchley Healthcare Ventures located?

Finchley Healthcare Ventures is headquartered in Montreal, CA.

Finchley Healthcare Ventures

Venture capital

Montreal · Seed–Late Stage · 10 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

The firm backs companies developing innovative, transformative prescription medicines aimed at addressing diseases not adequately served by current therapies. It is interested in a broad range of modalities, from small molecules and antibodies to breakthrough technologies such as nanotechnologies. Investment targets span companies approaching their first clinical trial through to those further along in development, with the goal of demonstrating proof of concept in humans. Beyond capital, the firm offers access to a network of professionals in medicine, pharmaceutical R&D, manufacturing, and commercialization to support product optimization and development. It also invests in life sciences venture funds and operates without geographic restriction.

Invests inBiotech Digital Health Healthtech Medical Devices Canada Global Montreal North America United States

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Late Stage

Montreal, QC, CA

Instruments

Equity

Founded

2022

Last 12 months

1 investment

AUM

$86M

Tracked investments

Team · 10 people

from the firm's website & public directories

David Goodman· President

Executive Chairman of the Board of Pharmascience Inc. and its former CEO (2006-2022), he holds a Commerce degree from McGill and a Ph.D. in Pharmacology from the University of Virginia, and serves on several company and nonprofit boards.

d•••@finchleyhcv.comreveal

Pierre Beauparlant· Executive Managing Director

With over 25 years in large pharma and venture-backed biopharma, he previously was a venture partner at Sanderling Ventures and CEO of several portfolio companies; he holds a Ph.D. in microbiology and immunology from McGill University.

Camille Couture· Associate (Investment Analyst)

Joined Finchley in 2024 to support evaluation of therapeutic innovations; she holds a Ph.D. in Microbiology and Immunology from Université de Montréal and completed private capital governance and science entrepreneurship programs.

Caroline Verner· Executive assistant

Joined Finchley in 2022 as an executive assistant supporting David and Morris Goodman and Pierre Beauparlant; she previously worked for many years at Bombardier Aerospace and later Pharmascience.

Dominic Caron· Director Finance & Compliance

Oversees finance and administration, supporting valuation and investment processes; he previously held finance roles at Pharmascience, holds an M.Sc. from HEC Montreal and is a CFA charterholder.

Ildiko Mehes· Director (Board of Directors)

A pharmaceutical industry board member and former executive with over 20 years of experience; she previously held senior legal and business roles at Teva Pharmaceuticals and began her career as a litigator at Goodmans LLP.

Jeff Wasserstein· Chairman (Board of Directors)

A senior investment banker at Greenhill & Co. since 2012 advising on biotech, specialty pharma and generics transactions, with prior senior roles at Fougera, Dr. Reddy's Laboratories and Schering-Plough.

Jeff Wassertein· J.D. – Chairman

Investment banker and pharma industry veteran with 20+ years of senior management experience. He advises on complex biotechnology, specialty pharmaceuticals, and generics transactions, with prior leadership roles building and scaling pharma businesses.

Philippe Lavoie· Senior Financial Analyst

Joined Finchley in 2025 to review portfolio companies' financial statements and support investment decisions; a CPA auditor formerly at Ernst & Young, he holds degrees from HEC Montréal.

Gabrielle Bertier· Associate (Senior Analyst)

Joined Finchley in 2023 to evaluate therapeutic innovations; previously Health Policy and Reimbursement Manager at Imagia Canexia Health, she holds a Ph.D. in Human Genetics from McGill University.

g•••@finchleyhcv.comreveal

What they invest in

from 1 of 1 portfolio companies

AI & Machine Learning ×1Biotech ×1

Investments · 1 tracked

founders shown can be your intro path

Coultreoncoultreon.com inApr 2026 · $125M

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)

Co-investorsLongwood Fund Sofinnova Ventures BAM Elevate Forbion Luma Group Novo Holdings +1 more

Portfolio news

latest coverage across their companies

Coultreon Biopharma secures $125M to advance SIK3 drug

Coultreon · bioxconomy.com · Apr 29, 2026

Frequently asked questions

What stage does Finchley Healthcare Ventures invest at?: Finchley Healthcare Ventures invests at the Seed, Series A, Series B, Late Stage stages.
What sectors does Finchley Healthcare Ventures focus on?: Finchley Healthcare Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Finchley Healthcare Ventures located?: Finchley Healthcare Ventures is headquartered in Montreal, CA.

Similar investors

Excel Venture Management

Excel Venture Management is a venture capital firm that builds and invests in companies applying life science technologies to problems in healthcare and other areas.

$1M – $5M

Blue Venture Funds

The Blue Venture Fund is a partnership among participating Blue Cross Blue Shield companies, the BCBS Association, and Sandbox Industries that invests in healthcare technology, healthcare services, and clinical sciences companies. It aims to reduce costs and improve health outcomes for Blue Plan members.

$1M – $20M

OneVentures

OneVentures is a later-stage venture capital firm that backs technology and healthcare companies, providing growth equity and credit alongside strategic and operational support.

$3.3M – $13.2M

SPRINGROCK VENTURES

SpringRock Ventures is a Seattle-based venture firm investing in the convergence of healthcare and information technology, backing companies across digital health, medical devices, oral health, healthcare SaaS and related innovation.

$2M – $5M

Easton Capital

Easton Capital is a venture capital fund focused on healthcare and life sciences, backing capital-efficient companies whose products or services improve care or reduce costs.

$10M – $20M